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Raman spectroscopy is an optical technique, which provides a measure of the molecular composition of tissue. Raman spectra were
recorded in vitro from both benign and malignant prostate biopsies, and used to construct a diagnostic algorithm. The algorithm was
able to correctly identify each pathological group studied with an overall accuracy of 89%. The technique shows promise as a method
for objectively grading prostate cancer.
British Journal of Cancer (2003) 89, 106–108. doi:10.1038/sj.bjc.6601059 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: prostate cancer; benign prostatic hypertrophy; Raman spectroscopy; Gleason score
                            
Raman spectroscopy is an optical technique that utilises mole-
cular-specific, inelastic scattering of light photons to interrogate
biological tissues (Mahadevan-Jansen et al, 1998). When tissue is
illuminated with laser light, photons interact with intramolecular
bonds present within the tissue. When occurs, the photon donates
energy to or receives energy from the bond, producing a change in
the bond’s vibrational state. When it subsequently exits the tissue,
the photon has an altered energy level and, therefore, has a
different wavelength compared to the original laser light. This
change in the photon’s energy is known as the ‘Raman shift’ and is
measured in wavenumbers. Photons interacting with different
biochemical bonds within the tissue, undergo different Raman
shifts, which taken together, form the ‘Raman spectrum’. The
Raman spectrum is a plot of intensity against Raman shift, in
wavenumbers. As the Raman Shift is inversely proportional to the
change in the photons’ wavelength, wavenumbers are expressed in
units of cm
 1. The Raman spectrum is a direct function of the
molecular composition of the tissue and can therefore give a truly
objective picture of the pathology. This is in contrast to Gleason
grading, which is subjective and associated with considerable
interobserver variation in reporting (Allsbrook et al, 2001a,b). A
previous study has confirmed that it is possible to record good-
quality Raman spectra from prostatic tissue (Crow et al, 2002); this
study evaluates the ability of Raman spectroscopy to differentiate
between different prostatic pathologies in vitro.
MATERIALS AND METHODS
Ethical approval was obtained to take an extra core at prostate
biopsy procedures. These biopsies were snap frozen in liquid
nitrogen and transferred to a  801C freezer for storage. A frozen
section was taken from each biopsy and processed for standard
histological examination, and the remainder of the biopsy was
retained at  801C. The sections were examined by a Consultant
Uro-Pathologist and histological diagnosis was made. Those
sections containing prostate adenocarcinoma were then examined
by a second Consultant Pathologist. In order to minimise the
effects of interobserver variation in Gleason scoring, biopsies were
only included in the study where an agreement on the Gleason
score (GS) was reached between the two pathologists. The position
of the prostate cancer within each section was carefully mapped so
that the region could subsequently be accurately targeted on the
Raman system. Biopsies were classified as benign prostatic
hyperplasia (BPH) or adenocarcinoma, with the adenocarcinoma
group further split into three groups depending on Gleason score
(GS less than seven, GS equal to seven and GS greater than seven).
The remainder of each prostate biopsy, from which the section
had been taken, was thawed in preparation for scanning on an
optimised Raman system (Renishaw System 1000). The system
employs a diode laser, producing 350mW of near-infrared light at
832nm. The laser was accurately targeted onto the tissue sample
via an ultralong working distance times 80 microscope objective.
This produces a laser spot of approximately 30 square microns,
which penetrates the tissue up to a depth of 100mm. The
information held within each Raman spectrum, therefore, relates
to a cluster of around 30 cells. Using the histological map provided
by the pathologist, the laser spot was targeted precisely onto an
area of known pathology within each sample. The laser spot was
then moved to random locations within this known area, to allow
up to 20 spectra to be recorded from each sample. Each Raman
spectrum was recorded on the spectrometer using an acquisition
period of 20s. A total of 450 spectra were measured from biopsies
taken from 27 different patients, 14 with BPH and 13 with
adenocarcinoma.
The spectral data were loaded onto the Matlab platform
(Mathworks Inc., Natick, Massachusetts), which, in conjunction
with the PLS Toolbox (eigenvector, Manson, Washington), was
used to perform the principal component fed, linear discriminant
analysis required to construct a diagnostic algorithm. The accuracy
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for each spectrum, was tested using ‘leave one spectrum out’
crossvalidation. This ensured that the data from the spectrum,
which was having its diagnosis predicted by the algorithm, had not
been used in constructing the algorithm being tested. A qualitative
analysis was also undertaken by comparing the mean of the spectra
recorded from BPH with the mean of the spectra recorded from all
prostate cancers.
RESULTS
Figure 1 shows mean, spectra for each pathological group studied.
In the interests of clarity, the spectra have been arranged so that
they are equally spaced with respect to the intensity axis. Figure 2
illustrates the prediction power of the algorithm, with the
algorithm-predicted diagnosis plotted against the confirmed
histological diagnosis. The large columns along the diagonal row
correspond to the correct prediction of histological diagnosis, with
the other small columns representing misdiagnoses by the
algorithm. The rows of Table 1 show the confirmed histological
diagnosis for each spectrum measured. The table columns show
the diagnosis predicted by the algorithm for each spectrum
measured. By reading across each row, the number of correct and
incorrect algorithm predictions, for each histological diagnosis,
can be viewed. Table 2 shows how the algorithm’s predictive
accuracy translates to sensitivity and specificity for each patholo-
gical group studied.
Figure 3 shows the mean spectra recorded from BPH and all
prostate cancers studied. Where visual differences in the peak
heights of the two spectra were noted, the relevant literature was
consulted for information as to the nature of these peaks (Hartman
et al, 1973; Manoharan et al, 1995; Boustany et al, 1996;
Mahadevan-Jansen, 1996; Manfait et al, 2000; Stone et al, 2002).
Although the biochemical designations of many peaks remain
uncertain, the differences between the two mean spectra suggest
that prostate cancer has increased levels of nucleic acids and
reduced levels of glycogen, when compared to BPH.
DISCUSSION
This study shows that Raman spectroscopy can be used to
accurately identify BPH and three different grades of prostatic
adenocarcinoma in vitro. Snap-frozen samples were used in order
to reproduce in vivo conditions as closely as possible, however,
work carried out by our group on other tissues has confirmed that
the technique can achieve similar results with formalin-fixed
specimens (Stone, 2001). The technique therefore shows promise
as a pathology tool providing a rapid, objective method for
diagnosing and grading prostate cancer. Work is ongoing to
increase the sample size of the study and also to determine whether
the technique is able to provide prognostic information for
individual patients with prostate cancer. Potential in vivo
applications include use, via a needle probe, to guide prostatic
biopsy and allow intraoperative assessment of tumour resection
margins.
The qualitative findings of reduced glycogen content and
increased nucleic acid content in malignant, compared to benign
pathologies, fit in with the findings of previous studies of the
larynx (Stone et al, 2000), colon (Feld et al, 1995), oesophagus
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Figure 1 The Mean Raman spectra for each pathological group studied.
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Figure 2 Bar chart and grid demonstrating the prediction power of the
diagnostic algorithm.
Table 1 Confirmed histological diagnosis against the diagnosis predicted
by the algorithm
Algorithm
Prediction BPH GSo7G S ¼7G S 47
Histological diagnosis BPH 192 6 9 0
GS o71 1 9 9 6 0
GS ¼7 10 6 70 0
GS 470 1 2 4 4
Figure 3 The mean Raman spectra recorded from BPH and all prostate
cancers studied.
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y(Bakker Schut et al, 1997) and cervix (Mahadevan-Jansen et al,
1998). These findings provide an insight into the type of molecular
differences, which allow the technique to differentiate between the
different pathologies. The use of multivariate spectral analysis
ensures that the diagnostic algorithm is constructed using all the
molecular information available from the Raman spectra. Retrieving
quantitative biochemical information from the Raman spectra of
prostatic tissue, however, currently remains a prospect for the future.
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Table 2 Sensitivity and specificity achieved by the diagnostic algorithm for each pathological group
BPH Gleason score o7 Gleason score ¼7 Gleason score 47
Total no. of spectra/
(total no. of patients)
207 (14) 116 (6) 86 (4) 47 (3)
Sensitivity 93% 85% 81% 94%
Specificity 92% 96% 96% 100%
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